NGL Fine Chem Ltd

NGL Fine Chem Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 February 2026, providing investors with an up-to-date view of its performance and prospects.

NGL Fine Chem Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 16 February 2026, providing investors with the most up-to-date insight into the stock’s performance and outlook.

NGL Fine Chem Ltd has emerged as a standout performer in the Pharmaceuticals & Biotechnology sector, delivering a remarkable 112.32% return over the past year, vastly outperforming the Sensex’s modest 8.86% gain. This micro-cap stock’s surge reflects a combination of robust financial results, strategic operational execution, and favourable market dynamics, positioning it as a compelling buy for investors seeking growth in a challenging environment.

NGL Fine Chem Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 February 2026, providing investors with the most up-to-date insights into the company’s performance and outlook.

NGL Fine Chem Ltd has surged to a fresh 52-week high of Rs.2596 on 5 Feb 2026, reflecting a robust rally that has propelled the stock well above its previous levels. This milestone underscores the company’s strong momentum in the Pharmaceuticals & Biotechnology sector amid a mixed market backdrop.

NGL Fine Chem Ltd has delivered a robust quarterly performance for December 2025, marking a significant turnaround in its financial trend. The company’s net sales, profitability, and earnings per share have all reached record highs, prompting an upgrade in its Mojo Grade from Hold to Buy. This improvement reflects a very positive shift in operational efficiency and market positioning within the Pharmaceuticals & Biotechnology sector.

NGL Fine Chem Ltd has surged to a fresh 52-week high of Rs.2188.25, reflecting robust momentum in the pharmaceuticals and biotechnology sector. This milestone underscores the stock’s significant outperformance relative to its peers and the broader market indices.

NGL Fine Chem Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a remarkable surge today, hitting its upper circuit limit of 20% to close at ₹2,164.20. This sharp rally was driven by robust buying interest, a significant gap-up opening, and sustained investor enthusiasm, marking a new 52-week high for the stock.

NGL Fine-Chem Limited has delivered a remarkable turnaround in Q3 FY26, with consolidated net profit surging 1,125.78% year-on-year to ₹15.69 crores, marking the strongest quarterly performance in the company's recent history. The Mumbai-based pharmaceutical intermediates manufacturer reported revenue of ₹127.51 crores, up 43.11% YoY, whilst operating margins expanded to 17.50%, signalling a decisive shift in operational efficiency. The stock responded with a dramatic 20% surge on February 4, 2026, closing at ₹2,188.25 and establishing a fresh 52-week high, as investors rewarded the micro-cap company's impressive recovery from the subdued performance witnessed in FY25.

NGL Fine Chem Ltd has demonstrated a significant shift in price momentum, supported by a suite of bullish technical indicators that have upgraded the stock’s outlook from a Sell to a Hold rating. The pharmaceuticals and biotechnology company’s shares surged 11.08% in a single day, closing at ₹1,706.75, reflecting renewed investor confidence and a positive technical trend reversal.

NGL Fine Chem Ltd has witnessed a notable shift in its technical momentum, transitioning from a mildly bullish stance to a more confident bullish trend across key indicators. Despite a recent day decline of 4.43%, the stock’s technical parameters, including MACD, RSI, and moving averages, suggest an improving outlook within the Pharmaceuticals & Biotechnology sector.

NGL Fine Chem Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 31 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 25 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

NGL Fine Chem Ltd has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance as of early 2026. Despite a strong day change of 5.26%, the stock’s technical indicators present a nuanced picture, reflecting both positive momentum and cautionary signals amid broader market volatility.

NGL Fine Chem Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 31 December 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 14 January 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

NGL Fine Chem Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bullish to a bullish trend as of early January 2026. This transition is supported by a confluence of technical indicators including MACD, RSI, moving averages, and Bollinger Bands, signalling a potential positive trajectory for the pharmaceutical and biotechnology company amid a challenging market backdrop.